About the Course
Estimated to affect approximately 70% of women during their lives, vulvovaginal candidiasis (VVC) can cause significant discomfort and distress. Unfortunately, management of VVC remains suboptimal, and many women are inadequately treated or receive inappropriate antibiotic therapy. This symposium will focus on the impact VVC has on patients as well as feature discussion on emerging treatment options that offer favorable safety and efficacy and may represent an improved approach to patient care.
- Jane Schwebke, MD
- Michael L. Krychman, MD, MPH
- Jack D. Sobel, MD
- Susan Tuddenham, MD, MPH
Upon completion of this activity, participants will:
- Have increased knowledge regarding the Burden of VVC among women
- Key differentiating characteristics for emerging treatments for VVC
- Data for emerging treatments for the treatment of VVC
Accreditation and Credit Designation Statement
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Join us on April 29, 2021, 6:00–7:00 p.m. ET.Register Now